四物汤通过调节肠道菌群与胆汁酸稳态改善纤维化肝损伤
本研究探讨四物汤对四氯化碳诱导小鼠纤维化肝损伤的治疗作用及机制。四物汤灌胃给药可改善肝胶原蓄积、肠道屏障损伤及炎症反应,重塑肠道菌群,调节胆汁酸组成,并激活FXR相关肠肝与肝脏通路。
要点
- 四物汤可减轻CCl4诱导的小鼠肝纤维化及肠道屏障损伤。
- 四物汤增加肠道Bacteroides和Lachnoclostridium相对丰度,降低Alistipes和Rikenellaceae相对丰度。
- 四物汤升高非结合胆汁酸(胆酸、鹅去氧胆酸),降低结合胆汁酸(牛磺胆酸、牛磺去氧胆酸)。
核心结论
- 四物汤通过减轻炎症反应、重建肠道菌群介导的胆汁酸稳态并激活FXR通路,保护CCl4诱导的纤维化肝损伤。
研究设计与样本
- 采用UHPLC-MS/MS对四物汤进行化学表征;C57BL/6小鼠每3天灌胃CCl4持续1周后,每日口服四物汤(5.2、10.4、20.8 g/kg)并继续CCl4攻击,共3周。
主要发现
- 四物汤改善CCl4诱导的肝纤维化,表现为肝胶原蓄积减少、肠道屏障损伤减轻及肝与肠道炎症反应改善。
- 16S rRNA测序显示四物汤增加纤维化小鼠肠道Bacteroides和Lachnoclostridium相对丰度,降低Alistipes和Rikenellaceae相对丰度。
- UHPLC-MS/MS显示四物汤升高循环中非结合胆汁酸(胆酸、鹅去氧胆酸),降低结合胆汁酸(牛磺胆酸、牛磺去氧胆酸)。
- 四物汤通过激活FXR-FGF15肠肝通路和FXR-SHP肝脏通路改善CCl4所致肝脏胆汁酸稳态失衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrotic liver injury is a progressive scarring event, which may permanently affect liver function and progress into devastating end-stage liver diseases due to the absence of effective therapies. Si-Wu-Tang (SWT), a traditional Chinese medicine formula used in clinic to treat gynecological disorders for centuries, has been investigated in recent preliminary findings for its role in alleviating chronic liver diseases. Here we aim to elucidate the therapeutic effects and possible mechanisms of SWT against fibrotic liver injury. METHODS: UHPLC-MS/MS was performed to investigate the chemical characterization of SWT. After intragastrically administered with carbon tetrachloride (CCl4) every 3 days for 1-week, C57BL/6 mice were orally administered with SWT (5.2, 10.4 and 20.8 g/kg) once daily for 3 weeks along with CCl4 challenge. Liver function was determined by the measurement of serum biomarkers, hematoxylin and eosin (H&E) and Masson's trichrome staining. Intestinal inflammatory infiltration and the disruption of intestinal barrier were examined by H&E and E-cadherin immunohistochemical staining. The microbial composition of intestinal content was determined by 16S rRNA sequencing. Serum bile acids (BAs) profiling was analyzed by LC-MS/MS. Simultaneously, the expression of genes of interest was determined by qPCR and western blot. RESULTS: SWT exhibited remarkable therapeutic effects on CCl4-induced liver fibrosis, as indicated by improved collagen accumulation in livers, intestinal barrier injury and hepatic and intestinal inflammatory response. Results of 16S rRNA sequencing revealed that SWT treatment strikingly restructured intestinal microbiota in fibrotic mice by increasing the relative abundances of Bacteroides and Lachnoclostridium and decreasing the relative abundances of Alistipes and Rikenellaceae. UHPLC-MS/MS data suggested that SWT altered the composition of BAs in circulation as evidenced by increased unconjugated BAs like cholic acid and chenodeoxycholic acid but decreased conjugated BAs including taurocholic acid and taurodeoxycholic acid, compared to that in CCl4 mice. Notably, SWT efficiently improved the imbalance of BA homeostasis in livers caused by CCl4 via activating farnesoid X receptor (FXR)-fibroblast growth factor 15 enterohepatic and FXR-small heterodimer partner hepatic pathways. CONCLUSION: SWT decreased inflammatory response, reconstructed gut microbiota-mediated BA homeostasis as well as activated FXR pathways, which eventually protected against CCl4-induced fibrotic liver injury.
引用
- Xue X, Wu J, Ding M, et al. Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis. Chin Med. 2021. PMID: 34736501. doi:10.1186/s13020-021-00524-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。